Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database.

This study aims to investigate the potential correlation between commonly prescribed attention-deficit/hyperactivity disorder (ADHD) medications and suicidal or self-injurious behaviors (SSIBs) among the pediatric population by exploring the FDA Adverse Event Reporting System (FAERS) database. The F...

Full description

Bibliographic Details
Published in:European Child & Adolescent Psychiatry Vol. 34; no. 8; pp. 2585 - 2598
Main Authors: Liu, Jinhua, Xue, Liping, Zeng, Fanxiang, Liu, Ying, Zhu, Yanting, Zhou, Jintuo, Zhang, Jinhua, Chen, Huajiao
Format: research tables/charts Journal Article
Published: Springer Nature Aug2025
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187670764&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 187670764
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10188827
        EJ3
      jtl: European Child & Adolescent Psychiatry
      issn: 10188827
      maglogo: N
    pubinfo:
      dt: Aug2025
      vid: 34
      iid: 8
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        187670764
        183475163
        187670764
        187670764
        10.1007/s00787-025-02694-w
        187670764
      ppf: 2585
      ppct: 13
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database.
      aug:
        au:
          Liu, Jinhua
          Xue, Liping
          Zeng, Fanxiang
          Liu, Ying
          Zhu, Yanting
          Zhou, Jintuo
          Zhang, Jinhua
          Chen, Huajiao
        affil: https://ror.org/050s6ns64 School of Pharmacy, Fujian Medical University, Fuzhou, China
      sug:
        subj:
          Attention Deficit Hyperactivity Disorder Drug Therapy
          Atomoxetine Therapeutic Use
          Atomoxetine Adverse Effects
          Suicidal Ideation Risk Factors
          Self-Injurious Behavior Risk Factors
          Risk Assessment
          Human
          Female
          Male
          Child
          Adolescence
          Pharmacovigilance
          Adverse Drug Event
          Methylphenidate
          Multivariate Analysis
          Logistic Regression
          Confidence Intervals
          Data Analysis Software
          Descriptive Statistics
          Funding Source
          Child: 6-12 years
          Adolescent: 13-18 years
          Female
          Male
      ab: This study aims to investigate the potential correlation between commonly prescribed attention-deficit/hyperactivity disorder (ADHD) medications and suicidal or self-injurious behaviors (SSIBs) among the pediatric population by exploring the FDA Adverse Event Reporting System (FAERS) database. The FAERS database (2004Q1–2023Q4) was queried and SSIBs cases associated with stimulants (methylphenidate, and amphetamine) or atomoxetine were identified. The signals for SSIBs were analyzed using disproportionate methods, and the accuracy of the results was validated through sensitivity analysis with multifactor logistic regression. Time-to-onset analysis explored factors affecting SSIBs manifestation. Disproportionality analysis revealed a significant negative association between methylphenidate and SSIBs, while atomoxetine exhibited a significant positive correlation with SSIBs. The frequency of SSIBs was lower with stimulants alone or with the combined use of stimulants and atomoxetine compared to atomoxetine alone. Time-to-onset analysis indicated that all cases were of the early failure type, with the median time to onset of SSIBs associated with atomoxetine occurring later than that linked to stimulants. Stratification by age showed that in the stimulant group, the median time to SSIBs was longer for patients aged 13–17 years compared to those aged 6–12 years. Conversely, the opposite trend was observed in the atomoxetine group. The observed differences in time to onset highlight the importance of individualized screening for SSIBs across various populations, ultimately improving patient outcomes in the follow-up of stimulants or atomoxetine recipients.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N